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Hepatocyte apoptosis is a key event in nonalcoholic fatty liver disease (NAFLD), and serum apoptotic markers are emerging as
surrogate markers for NAFLD. We studied the role of caspase-cleaved cytokeratin18 in the diagnosis of ﬁbrosis in a cohort of
127 morbidly obese patients and also performed a review of the literature biomarkers of NAFLD and ﬁbrosis. Here, we found that
cleavedcaspase18correlatedwithliversteatosisandliverinjuryasassessedbyserumtransaminaselevels.Furthermore,hepatocyte
apoptosis as assessed by cleaved CK18 and TUNEL staining correlated with the extent of ﬁbrosis as assessed by Sirius Red staining
and serum hyaluronic acid. These results underscore the important role of hepatocyte apoptosis in the pathogenesis of ﬁbrosis in
NAFLD, which led to the utilization of surrogate markers for apoptosis in the noninvasive diagnosis of NAFLD. We furthermore
reviewed current literature of biomarkers of NAFLD and ﬁbrosis.
1.Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most com-
mon chronic liver disease in Europe and the US with
a prevalence of up to 30% [1]. It is associated with obesity
and diabetes and is thus considered to be the hepatic man-
ifestation of the metabolic syndrome [2]. NAFLD ranges
from simple hepatic steatosis, characterized by triglyceride
accumulationinhepatocytes,toNonalcoholicsteatohepatitis
(NASH), which may be associated with ﬁbrosis and pro-
gression to cirrhosis or hepatocellular carcinoma [3]. While
the diagnosis of NAFLD is based on histology and patients
history, the increase in prevalence demands noninvasive
methods for diagnosis and surveillance.
Hepatocyte apoptosis was identiﬁed as a key feature of
NAFLD and correlates with disease severity [4]. Cytokeratin
18 (CK18) is an intermediate ﬁlament expressed in single-
layer epithelial tissues. During apoptosis, caspase-cleaved
CK18 is released into the cytoplasm and released into the
serumaftercelldeath.Therefore,solubleformsofextracellu-
lar CK18 in the serum are utilized to quantify activity of cell
death. Wieckowska et al. quantiﬁed cleaved CK18 fragments
in patients with NAFLD and found a correlation with the
occurrence of liver ﬁbrosis and hepatic inﬂammation. [5, 6]
The published results of a multicenter validation study by
Feldstein et al. revealed CK18 fragments as a predictor of
NASH versus simple steatosis [7].
Hyaluronic acid is a glycosaminoglycan, distributed
throughout epithelial tissues. Most of its disassembly takes
place in endothelial liver cells. Because of the lack of func-
tion, ﬁbrosis and cirrhosis lead to impaired clearance of
hyaluronic fragments. Several studies could show a corre-
lation between serum hyaluronic acid and ﬁbrosis stage in
chronic liver diseases, including NAFLD [8, 9].
Here, we evaluated caspase-cleaved CK18 and hyaluronic
acid as biomarkers for NAFLD and ﬁbrosis in a cohort of
127 patients who underwent bariatric surgery and compared
these results to the histological diagnosis, quantiﬁed by
NAFLD-activity score (NAS), as established by Kleiner et al.
[10]. In line with recent publications, we observed a clear
correlationbetweencaspase-cleavedCK18andliversteatosis.
It was noticed that high hepatocellular apoptosis rates2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
correlate with ﬁbrosis in NASH patients. Further current
literature review was also conducted on noninvasive markers
of NAFLD and ﬁbrosis.
2.MaterialsandMethods
2.1. Patients. A total of 127 morbidly obese patients (mean
age: 45 ± 10; 78.7% females, mean BMI: 52 ± 8) who
underwent bariatric surgery at a center for bariatric surgery
were included. Indication for bariatric surgery was made
according to National Institutes of Health (NIH) guide-
lines (BMI ≥ 40kg/m2 or ≥ 35kg/m2, plus comorbidities).
Subjects reporting excess alcohol consumption (>20g/day
in males or >10g/day in females) indicating alcoholic
liver disease were excluded. The surgeon’s choice—that is,
adjustable gastric band, Roux-Y, or gastric bypass surgery—
was based on the current guidelines as adapted to the
patient’s clinical conditions and comorbidities as well as on
clinical experience. Wedge liver biopsies were taken during
the procedure. A control group of 10 healthy volunteers (7
males; 3 females/median age: 26 ± 7.6 years) had an average
BMI of 22.4 ± 0.82kg/m. This study was approved by the
ethics committee (Institutional Review Board) of the Uni-
versity Hospital Essen. Patients volunteering were informed
about intraoperative risks and beneﬁts of wedge liver biopsy
a n dp r o v i d e di n f o r m e dc o n s e n t .
2.2. Sample Preparation. The degree of NAFLD was quan-
tiﬁed according to the NASH Scoring System. NAS score of
≥5 was deﬁned as NASH. CK18 serum levels and hyaluronic
acid were assessed in the sera of patients and healthy controls
using the M30-Apoptosense (Peviva, Bromma, Sweden) and
hyaluronic acid (Wako Chemicals, Neuss, Germany) ELISA
kits. The M30-Apoptosense assay detects a speciﬁc epitope
of caspase-cleaved CK18, which will further be referred to
as M30. All procedures were conducted according to the
manufacturers’ instructions.
2.3. Statistics. All data shown are mean ± SEM, if not stated
otherwise. Patients with and without NASH were compared
regarding metabolic characteristics, transaminases, NAS,
M30, and hyaluronic acid levels using independent samples
t-tests (Mann-Whitney test). Medline research was per-
formed in January 2011 with the search terms “serum
markers NAFLD” [11]. Analyses were performed with with
SPSS 15.0.1, Version 2006 (SPSS, Chicago, IL, USA) and
Graph Pad, version 5.03 (Graph Pad, Graph Pad Software
Inc., CA, USA).
3. Results
3.1. Patient Characteristics. The clinical characteristics of the
56patientswithNASH(NAS ≥5)incomparisonto71NAFL
patients (NAS < 5) are stated in Table 1. In patients with
NASH,riskfactorsofthemetabolicsyndromeastriglycerides
and fasting glucose were higher in comparison to patients
with NAFL. However, there were no signiﬁcant diﬀerences
in between the two groups.
Table 1: Characterization of NASH and NAFL patients.
NAFL (n = 71) NASH (n = 56) P value
Age (yr) 44.6 ± 1.3 40.7 ± 1.9 n.s.
Gender (w) 56 (79%) 44 (79%) n.s.
BMI (kg/m2) 53.6 ± 0.9 51.2 ± 1.1 n.s.
Fasting-glucose (mg/dL) 106.8 ± 5.2 115.3 ± 6.6 n.s.
HbA1c (%) 5.8 ± 0.1 6.2 ± 0.2 n.s.
Total cholesterol (mg/dL) 191.3 ± 4.1 194.5 ± 5.7 n.s.
HDL cholesterol (mg/dL) 43.3 ± 1.2 46.1 ± 2.1 n.s.
LDL cholesterol (mg/dL) 130.7 ± 3.8 121.2 ± 5.4 n.s.
Triglycerides (mg/dL) 152.6 ± 21.0 157.3 ± 15.2 n.s.
Data are given as mean ± SEM or percentage aﬀected. BMI: Body Mass
Index.
3.2. Caspase-Cleaved CK18 Predicts Steatosis and Hepatocel-
lular Injury. As the NAS score consists of the individual
scoring values for steatosis, ballooning, and lobular inﬂam-
mation, a NAS ≥ 5 was accompanied with signiﬁcantly
higher scores for the individual characteristics of NAFLD.
A se x p e c t e d ,M 3 0w a se l e v a t e di nN A S Hp a t i e n t s( F i g u r e s
1(a), 2(a),a n d2(b)). Accordingly, serum transaminase levels
were elevated in NASH patients (Figure 1(b)). The artiﬁcial
cut-oﬀ for M30 to predict NASH (275U/L), established and
validated by the Feldstein group, in our cohort corresponded
with histological steatosis, but not lobular inﬂammation [7].
In serological NASH, ballooning and NAS score were only
modestly elevated (Figure 1(c)). However, alanine amino-
transferase (ALT) and aspartate aminotransferase (AST)
levels were signiﬁcantly higher in patients with plasma levels
of M30 ≥275U/L, indicating hepatocellular damage, despite
no histological signs of lobular inﬂammation (Figure 1(d)).
3.3. Fibrosis in NAFLD Correlates with Apoptosis, Not with
HistologicalFeaturesofNASH. Interestingly,abouttwo-third
of our cohort had stage-2 ﬁbrosis (Figures 2(a) and 2(b)).
We did not ﬁnd an increase in ﬁbrosis score in patients
with a NAS ≥ 5. However, morphometrically quantiﬁed liver
collagen (Sirius Red) and serum hyaluronic acid were both
elevated in histological NASH versus NAFL (Figures 3(a),
2(e),and2(f)).Advancedﬁbrosiswasfurtherassociatedwith
more TUNEL positive cells per visual ﬁeld in liver sections,
and serum hyaluronic acid was dramatically increased in
patients with advanced ﬁbrosis (Figures 3(b), 2(c),a n d
2(d)). Accordingly, M30 levels were higher in patients with
advanced ﬁbrosis, while the NAS score was not diﬀerent
between the groups at all (Figure 3(c)). This supports the
above-mentioned observation that ﬁbrosis is associated with
hepatocellular apoptosis, rather than lobular inﬂammation.
In this context, the number of TUNEL positive cells in livers
was signiﬁcantly correlated with the percentage of Sirius Red
positive area in the visual ﬁeld and M30 was signiﬁcantly
correlated with serum hyaluronic acid (Figure 3(e)).
4. Discussion andReview
In our cohort of 127 morbidly obese patients, caspase-
cleaved CK18 correlated with hepatic steatosis but notJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
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Figure 1: NAS versus M30 assay. As expected, the NAS score correlates with its individual parameters steatosis, ballooning, and lobular
inﬂammation. M30 is higher in patients with histologically established NASH (NAS  5;) (a). Serum transaminase levels are higher in
patients with NASH (b). M30 correlates with histological steatosis, but not lobular inﬂammation (c). ALT and AST are signiﬁcantly higher
in patients with M30  2 7 5U / L( d ) .( ∗= P<. 05; #= P<. 01).
lobular inﬂammation as assessed by histological scoring.
Still, AST and ALT were signiﬁcantly higher in patients with
CK18 levels above the established cut-oﬀ for NASH, indicat-
ingadiscrepancybetweenhistologicalassessedinﬂammation
and actual liver injury. Interestingly, the degree of ﬁbrosis
did not correspond to the NAS score, while a high apoptosis
rate, as assessed by TUNEL staining in liver tissue and
assessment of serum caspase-cleaved CK18, correlated with
increased ﬁbrosis. This is in line with recent publications,
that hepatocyte apoptosis, rather than hepatic inﬂammation,
is a key trigger of hepatic stellate cell activation and thus
ﬁbrogenesis [12, 13]. Taken together, our data indicate that
biomarkers in NAFLD might reveal more information than
standardhistologicalscoring.Inthefollowing,wewillreview
the emerging data on serum markers in NAFLD, a ﬁeld that
is continuously growing (Figure 3(f)).
To date, liver biopsy and histological assessment of liver
steatosis, ballooning, and lobular inﬂammation in H&E
staining remain the gold standard for diagnosis of NASH
[10]. However, despite a low rate of overall complications,
percutaneous liver biopsy remains an invasive procedure
with the risk of potentially lethal hemorrhage and infections
and is further complicated in the growing number of obese
patients with NAFLD [14, 15]. Furthermore, several studies
suggestedarelativelyhighrateofsampleandinterpretational
errors [16]. Given the increasing prevalence of NAFLD,4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 2: Histological assessment in NAFLD. NASH is histologically deﬁned by increased steatosis, ﬁbrosis, and lobular inﬂammation (a/b).
Apoptosis is a key feature of NASH, which is accompanied by an increase in TUNEL positive cells (c/d). Hepatocyte apoptosis triggers HSC
activation and thus ﬁbrogenesis. Representative slides with quantiﬁcation of collagen by Sirius red staining (e/f).
noninvasive markers for NAFLD are a promising approach
not only for screening reasons.
In 2006, Wickowska et al. quantiﬁed soluble caspase-
cleaved CK18 with a speciﬁc M30-ELISA and found a cor-
relation with the histological staging in NAFLD patients [5].
This was validated by the same group and in a cohort of
patients who underwent bariatric surgery, an M30-cutoﬀ
value of 275U/L was established to discriminate simple
steatosis from NASH [7, 17]. We and others were able
to show that M30 correlates with fatty acid transporter
expression in liver tissue and speciﬁc fatty acids in the serum
[18, 19]. In a cohort of patients with polycystic ovarial
syndrome, we could identify a high rate of patients with
NASH utilizing this assay [20]. Lately, the Feldstein group
enhanced sensitivity and speciﬁcity of NASH detection by
detection of soluble FAS and FAS ligand additional to
M30 and established an apoptotic index in the noninvasive
diagnosis of NASH [21].
As mentioned above, we found not only a correlation
of M30 with hepatic steatosis but also a good correlation
between the apoptosis rate and markers for ﬁbrosis in our
cohort, which is in line with observations from other groups
[22]. Hepatocyte apoptosis is known to activate hepatic stel-
late cells via formation of apoptotic bodies, which are either
directly stimulating hepatic stellate cells or are engulfed by
Kupﬀer cells, which in turn activate stellate cells [23, 24].
Noninvasive diagnosis of ﬁbrosis in NAFLD is complicated
by the high rate of obese patients compared to hepatitis C
infection. Transient elastography, a method that accurately
predictsﬁbrosisstageinhepatitisCpatients,faceslimitations
in NASH patients, as accuracy is dramatically reduced in
obese individuals [25]. Thus, serum biomarkers might be a
promising alternative in NAFLD patients. Hyaluronic acid
has been implied as a good biomarker for ﬁbrosis and was
correlatedwiththeapoptosisrateinourcohort[9].However,
several multipanel tests are among the most promising inJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
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Figure 3: Association between apoptosis and ﬁbrosis. Although ﬁbrosis, as quantiﬁed by a pathologist in H&E sections is not increased in
NASH,collagen stainingand serumhyaluronic acid indicate moreﬁbrosisinNASH(a).Hepatocyte apoptosisand serumhyaluronic acid are
increased in advanced ﬁbrosis (b, c). Cell death rate is associated with ﬁbrotic areal in histological slides from NASH patients (d). Hyaluronic
acid is correlated with serum cleaved CK18 (e). Linear increase in publications/year on serum markers of NAFLD (f).6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
noninvasive diagnosis of ﬁbrosis. These tests consist of
diﬀerent serum parameters, some even include assessment of
hyaluronic acid and are validated in cohorts of hepatitis C
patients but might as well be useful in patients with NAFLD,
although validation studies still need to prove accuracy in
this cohort [26, 27].
5. Conclusion
Taken together, because of the nature of NAFLD and the
increase in prevalence, there is an increasing demand for
noninvasive markers of NAFLD and ﬁbrosis. Since hepato-
cyteapoptosis isakeyfeatureofNAFLDandalsocontributes
to ﬁbrogenesis, assessment of soluble markers of apoptosis
appears to be a good alternative to liver biopsy in these
patients. In fact, these methods might give better insight into
the status and prognosis of liver disease than standard
H&E assessment. However, especially ﬁbrotic markers need
further validation since the high rate of obesity might con-
found these tests.
Abbreviations
NAFLD: Nonalcoholic fatty liver disease
NAS: Nonalcoholic fatty liver disease histological score
NASH: Nonalcoholic steatohepatitis.
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